(Q46216431)

20 December 2017

title

Cost-effectiveness of three different vaccination strategies against measles in Zambian children (English)

1 reference

20 December 2017

cost-effectiveness analysis

0 references

1 reference

1 reference

1

Gustavo H Dayan

1 reference

20 December 2017

Peter M Strebel

6

object named as

Peter Strebel

1 reference

20 December 2017

author name string

Lisa Cairns

2

1 reference

20 December 2017

Nalinee Sangrujee

3

1 reference

20 December 2017

Anne Mtonga

4

1 reference

20 December 2017

Van Nguyen

5

1 reference

20 December 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

20 December 2017

published in

Vaccine

1 reference

20 December 2017

volume

22

1 reference

20 December 2017

issue

3-4

1 reference

20 December 2017

page(s)

475-484

1 reference

20 December 2017

The effect of dose and strain of live attenuated measles vaccines on serological responses in young infants

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.007

STUDIES ON IMMUNITY TO MEASLES

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.007

Further-attenuated measles vaccine: characteristics and use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.007

Measles reimmunization in children seronegative after initial immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.007

Adverse events following measles-mumps-rubella and measles vaccinations in college students

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.007

Cost-effectiveness and cost-benefit analyses of vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.007

Benefits, risks and costs of immunization for measles, mumps and rubella

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.007

Costs and benefits of a second measles inoculation of children in Israel, the West Bank, and Gaza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.007

A benefit-cost analysis of two-dose measles immunization in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.007

Decline in measles mortality: nutrition, age at infection, or exposure?

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.007

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.007

inferred from DOI database lookup

7 January 2021

based on heuristic

Measles incidence, case fatality, and delayed mortality in children with or without vitamin A supplementation in rural Ghana.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.007

The Global Burden of Measles in the Year 2000—A Model that Uses Country‐Specific Indicators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.007

Measles control in young infants: where do we go from here?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.007

Decline in measles case fatality ratio after the introduction of measles immunization in rural Senegal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.007

Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps, and rubella

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.007

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2003.07.007

1 reference

20 December 2017

1 reference

20 December 2017